Is liver toxicity from tigecycline greater in the elderly?

Who is at higher risk for liver toxicity from tigecycline?

Research suggests that elderly patients may be at a higher risk for liver toxicity associated with tigecycline [1]. According to clinical trials and observational studies, elderly patients (defined as those aged 65 or older) tend to have increased levels of liver enzymes, which can be a sign of liver damage.

Why are elderly patients at increased risk?

Several factors contribute to the increased risk of liver toxicity in elderly patients taking tigecycline. These include:

* Age-related changes: As people age, their livers become less efficient at metabolizing drugs, which can lead to increased drug levels and increased risk of toxicity [2].
* Comorbidities: Elderly patients often have multiple health conditions, such as diabetes, hypertension, and kidney disease, which can interact with tigecycline and increase the risk of liver toxicity.
* Polypharmacy: Elderly patients are more likely to be taking multiple medications, including other drugs that can interact with tigecycline and increase the risk of liver toxicity.

What are the clinical implications?

The increased risk of liver toxicity in elderly patients taking tigecycline has important clinical implications. Clinicians should carefully monitor elderly patients for signs of liver toxicity, such as elevated liver enzymes, jaundice, and fatigue. If liver toxicity is suspected, clinicians should consider alternative antibiotics or reduce the dose of tigecycline to minimize the risk of liver damage.

References:

[1] https://www.drugpatentwatch.com/pharma/tigecycline
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739568/